Pharmaceutical

RedHill Biopharma is discontining its commercialization agreements for its legacy products and focusing on its lead commercial products.

RedHill Biopharma (NASDAQ:RDHL,TASE:RDHL) announced its decision to discontinue its co-promotion and commercialization agreements for Donnatal and EnteraGam and focus on its lead commercial products, Talicia and Aemcolo.

As quoted in the press release:

RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed. RedHill has been promoting Donnatal® and EnteraGam® since mid-2017.

“Prioritizing our commercial efforts allows us to focus on our most valuable products, Talicia® and Aemcolo®, as well as giving us capacity to bring on other important products, which are currently under discussion,” said Dror Ben-Asher, RedHill’s Chief Executive Officer. “Over the past 2.5 years, we’ve established a full U.S. commercial operation including a seasoned sales force, and built relationships with thousands of gastroenterologists, primary care and other healthcare providers across the country ahead of the planned Talicia® launch later this quarter. We would like to thank our partners at Advanz Pharma and Entera Health for the fruitful partnerships.”

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.38-33.45
NASD11028.74-149.16
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1806.02-12.80
Silver20.22-0.52
Copper3.68-0.03
Palladium1932.50-29.50
Platinum894.50-24.50
Oil105.79+0.03
Heating Oil3.85+0.02
Natural Gas5.66+0.24

DOWNLOAD FREE REPORTS

×